<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35587919</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Calycosin plays a protective role in diabetic kidney disease through the regulation of ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>990</StartPage>
          <EndPage>996</EndPage>
          <MedlinePgn>990-996</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2022.2067572</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="UNASSIGNED">Diabetic kidney disease (DKD) is a devastating complication of diabetes. Renal functional deterioration caused by tubular injury is the primary change associated with this disease. Calycosin shows protective roles in various diseases.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This study explored the function and underlying mechanism of calycosin in DKD.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">HK-2 cells were treated with 25 mM high glucose (HG) to establish a renal tubule injury cell model. Then, the viability of cells treated with 0, 5, 10, 20, 40 and 80 μM of calycosin was measured using Cell Counting Kit-8. For the <i>in vivo</i> model, db/db mice were treated with 10 and 20 mg/kg/day of calycosin; db/m mice served as controls. The histomorphology was analyzed via haematoxylin and eosin staining.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">HG-induced decreased expression of glutathione (491.57 ± 33.56 to 122.6 ± 9.78 μmol/mL) and glutathione peroxidase 4 (inhibition rate 92.3%) and increased expression of lactate dehydrogenase (3.85 ± 0.89 to 16.84 ± 2.18 U/mL), malondialdehyde (3.72 ± 0.66 to 18.2 ± 1.58 nmol/mL), lipid ROS (4.31-fold increase) and NCOA4 (7.69-fold increase). The effects induced by HG could be blocked by calycosin. Moreover, calycosin alleviated the HG-induced decrease of cell viability and the increase of lipid ROS, but erastin could block the effects caused by calycosin. The <i>in vivo</i> model showed that calycosin alleviated the renal injury caused by diabetes.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSION" NlmCategory="UNASSIGNED">Calycosin has a protective effect on diabetic kidney disease; ferroptosis may be involved in this process.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Di</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>TCM Institute of Kidney Disease, Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Peicheng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Jiandong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>TCM Institute of Kidney Disease, Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Chaoyang</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007529">Isoflavones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>09N3E8P7TA</RegistryNumber>
          <NameOfSubstance UI="C121707">7,3'-dihydroxy-4'-methoxyisoflavone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003928" MajorTopicYN="Y">Diabetic Nephropathies</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007529" MajorTopicYN="N">Isoflavones</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">High glucose</Keyword>
        <Keyword MajorTopicYN="N">glutathione peroxidase 4</Keyword>
        <Keyword MajorTopicYN="N">lipid reactive oxygen species</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>15</Hour>
          <Minute>51</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35587919</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2022.2067572</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
